Clinical Trial Update: Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial assessing FG-4592 for anemia in lower-risk myelodysplastic syndrome completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelodysplastic Syndrome

Drugs mentioned

• FG-4592 (roxadustat)

Snippet

Sponsor: Kyntra Bio | Conditions: Anemia, Myelodysplastic Syndrome | Phase 2, Phase 3 | Status: COMPLETED